Given that the main driving forces in GIST pathogenesis are the auto-activated, mutant KIT receptor tyrosine kinase gene and, less commonly, the platelet-derived growth factor receptor alpha (PDGFRA) [1,2,3], targeted therapies are currently accepted as the most effective therapeutic option for adjuvant and non-adjuvant settings, as well. The gene discussed is PDGFRA; the disease is gastrointestinal stromal tumor.